Herein, this study was carried out aimed at exploring the pharmacological effects of BAK in the setting of hyperglycemia-induced diabetic cardiomyopathy and elucidate whether SIRT1/Nrf2 signaling is involved in its protective molecular mechanisms both in vivo and in vitro. The gene discussed is SIRT1; the disease is Hyperglycemia.